Ofatumumab monotherapy in fludarabine-refractory chronic lymphocytic leukemia: final results from a pivotal study

Authors:

Abstract
While fludarabine-based regimens are a standard for treatment of chronic lymphocytic leukemia (CLL), patients who become refractory to fludarabine have had low response rates with salvage therapy and poor survival outcomes.[1][1]–[3][2] We reported that ofatumumab, a human monoclonal antibody that

This publication has 14 references indexed in Scilit: